| Overview |
| bsm-0933M-PE-Cy5.5 |
| GLP-1 (1G9) Monoclonal Antibody, PE-Cy5.5 Conjugated |
| WB |
| Human, Mouse, Rat |
| Specifications |
| PE-Cy5.5 |
| Mouse |
| KLH conjugated synthetic peptide derived from human GLP-1 |
| 1-31/31 |
| Monoclonal |
| 1G9 |
| IgG |
| 1ug/ul |
| Purified by Protein G. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| GCG; GLP 1; glucagon; Glucagon like peptide 1; GRPP; GLP-17-36; GLP-17-37; Oxyntomodulin; OXM; OXY; GLUC_HUMAN. |
| Glucagon plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. GLP-1 is a potent stimulator of glucose-dependent insulin release. Play important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in thesuppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Have growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin. Belongs to the glucagon family. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz